beta-alanine has been researched along with Multiple Sclerosis in 2 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Future treatments of multiple sclerosis (MS), a chronic autoimmune neurodegenerative disease of the central nervous system (CNS), aim for simultaneous early targeting of peripheral immune function and neuroinflammation." | 1.56 | Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. ( Balletta, S; Bruno, A; Bullitta, S; Buttari, F; Caioli, S; Centonze, D; De Vito, F; Dolcetti, E; Fresegna, D; Gentile, A; Guadalupi, L; Mandolesi, G; Musella, A; Nencini, M; Rizzo, FR; Sanna, K; Stampanoni Bassi, M; Vanni, V; Vitiello, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Musella, A | 1 |
| Gentile, A | 1 |
| Guadalupi, L | 1 |
| Rizzo, FR | 1 |
| De Vito, F | 1 |
| Fresegna, D | 1 |
| Bruno, A | 1 |
| Dolcetti, E | 1 |
| Vanni, V | 1 |
| Vitiello, L | 1 |
| Bullitta, S | 1 |
| Sanna, K | 1 |
| Caioli, S | 1 |
| Balletta, S | 1 |
| Nencini, M | 1 |
| Buttari, F | 1 |
| Stampanoni Bassi, M | 1 |
| Centonze, D | 1 |
| Mandolesi, G | 1 |
| Moore, TJ | 1 |
| Furberg, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study[NCT05245344] | 154 participants (Anticipated) | Observational | 2022-04-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for beta-alanine and Multiple Sclerosis
| Article | Year |
|---|---|
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
Topics: Animals; Anti-Inflammatory Agents; beta-Alanine; Cell Line; Central Nervous System; Disease Models, | 2020 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clin | 2012 |